Wedbush Reiterates Outperform on Longboard Pharmaceuticals, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a price target of $11.
October 12, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Longboard Pharmaceuticals has received an Outperform rating from Wedbush, with a maintained price target of $11.
The Outperform rating from Wedbush indicates a positive outlook for Longboard Pharmaceuticals. The maintained price target of $11 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100